Provided by Tiger Fintech (Singapore) Pte. Ltd.

Abeona Therapeutics

6.80
+0.23503.58%
Volume:3.04M
Turnover:20.80M
Market Cap:329.79M
PE:-4.38
High:7.04
Open:6.54
Low:6.38
Close:6.56
Loading ...

Abeona Therapeutics Up Over 22%, on Pace for Largest Percent Increase Since October 2022 -- Data Talk

Dow Jones
·
Yesterday

Abeona Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
30 Apr

Abeona Therapeutics price target raised to $20 from $15 at H.C. Wainwright

TIPRANKS
·
30 Apr

ABEO: Zevaskyn™ Approved by FDA; Raising Valuation to $11…

Zacks Small Cap Research
·
30 Apr

Abeona Therapeutics Says US FDA Approves Zevaskyn to Treat Wounds in Patients With Genetic Skin Disease

MT Newswires Live
·
29 Apr

Abeona Therapeutics Says Gene Therapy Zevaskyn's Wholesale Acquisition Cost or U.S. List Price Is $3.1 Million

THOMSON REUTERS
·
29 Apr

BUZZ-U.S. STOCKS ON THE MOVE-Spotify, Abeona, Honeywell

Reuters
·
29 Apr

Abeona Therapeutics Shares up 13.1% Premarket After US FDA Approves Co's Gene Therapy for Rare Genetic Skin Disorder

THOMSON REUTERS
·
29 Apr

BUZZ-Abeona rises on FDA approval for skin disorder therapy

Reuters
·
29 Apr

BRIEF-US FDA Approves ZEVASKYN, First And Only Cell-Based Gene Therapy For Patients With Recessive Dystrophic Epidermolysis Bullosa

Reuters
·
29 Apr

US FDA approves first cell-based gene therapy for rare genetic skin disorder

Reuters
·
29 Apr

Abeona Therapeutics Inc - Zevaskyn to Be Available Through Qualified Treatment Centers in 3Q 2025

THOMSON REUTERS
·
29 Apr

U.S. FDA Approves Zevaskyn™ (Prademagene Zamikeracel), the First and Only Cell-Based Gene Therapy for Patients With Recessive Dystrophic Epidermolysis Bullosa (Rdeb)

THOMSON REUTERS
·
29 Apr

U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

GlobeNewswire
·
29 Apr

Abeona Therapeutics Inc : Stifel Resumes Coverage With Buy Rating; Target Price $14

THOMSON REUTERS
·
08 Apr

Abeona Therapeutics Rises in Volume Spike, Last up 5.6%

THOMSON REUTERS
·
04 Apr

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
01 Apr

ABEO: Countdown to PDUFA Date of April 29, 2025…

Zacks Small Cap Research
·
24 Mar

Abeona Therapeutics Price Target Maintained With a $15.00/Share by HC Wainwright & Co.

Dow Jones
·
24 Mar

Abeona Therapeutics: Positive Outlook Amid FDA Hopes

TIPRANKS
·
22 Mar